|
Dr. Dagger has more than 29 years experience in chemical process development, pilot plant operations and design, contract synthesis and cGMP as applied to Active Pharmaceutical Ingredients. He was educated at Temple University, where he was awarded a B.A in biology and an M.A. in organic chemistry, and Bryn Mawr College where he was awarded a Ph.D. in organic chemistry under the direction of Dr. Charles Swindell. He has been awarded 7 patents, and is a co-author on multiple publications and presentations. During a 19 year career at SK&F he was involved in chemical process R&D, preparation of clinical trial API, technical transfer to production and production of APIs in the areas of cephalosporin antibiotics, angiotensin II receptor antagonists, ?-blockers, leukotriene antagonists, dopamine receptor antagonists and peptides (solution phase synthesis). At Eisai Research Institute he held the positions of Senior Scientist, Manager of Process R&D, Director of Chemical Technologies and Executive Director of Chemical Development. During his career at Eisai he led chemical process R&D and the preparation of clinical supplies of API for Eisai�s lead candidate for treatment of sepsis. He was on the team responsible for the construction and validation of the development site. Dr. Dagger was responsible for chemical process R&D, analytical chemistry, QC, QA, pilot plant operations and the development site facilities. As Vice President of Contract Synthesis for Cardinal Health he was a key member of RTP site management. He also helped start-up pharmaceutical companies identify and manage contract synthesis suppliers. | 